Examkin

Question

Difficulty: MediumRheumatology and Immunology

A 31-year-old man is diagnosed with active ankylosing spondylitis. His symptoms are currently confined to the axial skeleton, presenting as severe inflammatory back pain and profound morning stiffness. Arrange the following pharmacologic management steps in the correct chronological sequence for escalating his therapy, assuming he experiences inadequate clinical responses at each preceding stage.

  1. 1Initiate continuous, daily therapy with an initial nonsteroidal anti-inflammatory drug (NSAID) such as naproxen.
  2. 2Discontinue the first agent and trial a second, different NSAID (e.g., celecoxib) for 2 to 4 weeks.
  3. 3Initiate biologic therapy with a tumor necrosis factor (TNF) inhibitor, such as adalimumab.
  4. 4Switch to a biologic agent targeting interleukin-17 (IL-17), such as secukinumab.

Answer

The correct sequence of pharmacologic escalation for axial ankylosing spondylitis begins with an initial NSAID trial, followed by a second alternative NSAID trial, escalation to a TNF inhibitor, and finally transition to an IL-17 inhibitor.
The correct sequence precisely follows the Assessment of SpondyloArthritis international Society (ASAS) and American College of Rheumatology (ACR) guidelines for purely axial ankylosing spondylitis: First NSAID -> Second NSAID -> First-line Biologic (TNF inhibitor) -> Second-line Biologic (IL-17 inhibitor).

Step-by-Step Solution

1
Identify the extent of the patient's disease.
The patient has active ankylosing spondylitis strictly confined to the axial skeleton.
Establishing purely axial involvement is critical because it rules out the use of conventional synthetic DMARDs (e.g., methotrexate, sulfasalazine), which only work for peripheral arthritis.
2
Determine the initial first-line therapy.
Initiate a continuous NSAID (e.g., naproxen).
NSAIDs are the cornerstone of initial medical management for axial spondyloarthritis, providing excellent symptom control in a majority of patients.
3
Identify the required step prior to biologic escalation.
Trial a second, different NSAID.
Current rheumatology guidelines require the failure of at least two consecutive NSAID trials (typically 2-4 weeks each) before insurance approval and clinical indication for biologics are met.
4
Select the appropriate initial biologic therapy.
Initiate a TNF inhibitor (e.g., adalimumab).
TNF-alpha inhibitors are the preferred first-line biologic class for NSAID-refractory axial ankylosing spondylitis.
5
Determine the next step if the initial biologic fails.
Switch to an IL-17 inhibitor (e.g., secukinumab).
Upon failure of a TNF inhibitor, switching mechanisms of action to an IL-17 inhibitor or JAK inhibitor is the standard escalation pathway.

Key Concept

The sequential pharmacologic management of axial ankylosing spondylitis strictly requires failing at least two continuous NSAID trials before escalating to biologic therapies (TNF inhibitors, then IL-17 inhibitors).
Rate this question

Topics

Rheumatology and Immunology

More questions from this topic